TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06651970: A Multicentre, Open-label, Randomised Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Sever

Sponsor: AstraZeneca · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$318,720

Rescue Site Savings

+$212,480

Unlock Full NCT06651970 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06651970 Rescue Dossier →